Avenda Health Expands Unfold AI to Revolutionize Prostate Cancer Care in the Midwest
Avenda Health, a pioneering developer of artificial intelligence (AI) technology in healthcare, has recently expanded its state-of-the-art Unfold AI platform into the Midwest, partnering with the University of Michigan Health Weiser Center for Prostate Cancer. This initiative marks a significant advancement in prostate cancer care by integrating AI-based prostate cancer mapping technology into one of the country’s foremost urologic oncology programs.
Enhancing Prostate Cancer Detection and Treatment Planning
Prostate cancer remains one of the most common cancers among men, with statistics indicating that one in eight men will receive a diagnosis in their lifetime. Despite advances in conventional imaging and biopsy, many cases of clinically significant prostate cancer remain undetected or poorly defined, posing challenges for effective treatment.
Avenda Health’s Unfold AI addresses these challenges by providing a patient-specific, three-dimensional (3D) visualization of cancer. This FDA-cleared multimodal platform combines multiple data sources including imaging and pathology results to generate a comprehensive and personalized disease map. This map reveals tumor size, location, and spread with greater accuracy, guiding physicians in tailoring precise treatment strategies.
Unmatched Accuracy in Tumor Detection
Peer-reviewed studies have demonstrated the superior sensitivity and predictive capabilities of the Unfold AI platform. It increases physician sensitivity in identifying tumor extent from 37% with standard imaging to 97%, and accurately predicts cancer spread into adjacent anatomy with 92% accuracy compared to 52% for MRI alone. This technology essentially uncovers up to 20% of clinically significant prostate cancers that are invisible on standard prostate MRI.
Dr. Andrew M. Wood, a leading urological surgeon at University of Michigan Health, emphasizes the value of the platform: “Having access to Unfold AI adds a valuable tool to our evaluation and treatment of this disease, allowing for additional precision in tumor ablation procedures and a more personalized treatment paradigm tailored to each patient.”
Expanding AI-Guided Care Across Major Cancer Centers
Shyam Natarajan, PhD, Co-founder and CEO of Avenda Health, highlights that the collaboration with the University of Michigan Health represents an important step in deploying AI-guided prostate cancer care nationwide. The Unfold AI platform’s integration into major cancer centers will help streamline treatment planning and improve clinical decision-making, especially in the face of increasing rates of advanced prostate cancer.
Recognition and Reimbursement Milestones
A significant achievement of Avenda Health’s technology is that it became the first AI urology product to receive a Category III Current Procedural Terminology (CPT) code from the American Medical Association. This milestone facilitates national Medicare payment rates for outpatient hospital settings. Moreover, the platform has recently been included in Medicare Physician Fee Schedules covering additional geographic regions including the West Coast and Mountain West areas, increasing accessibility for patients and providers.
The Future of Prostate Cancer Management with AI
With population growth and aging demographics, prostate cancer cases—especially advanced disease—are expected to climb. Integrating advanced AI technologies like Unfold AI into clinical workflows can transform how clinicians detect, characterize, and treat prostate tumors, leading to more personalized and effective therapies.
By enabling detailed 3D cancer visualization and enhancing tumor detection sensitivity, Unfold AI empowers healthcare providers with data-driven insights. This innovation not only improves patient outcomes but also sets a new standard in prostate cancer management.
Stay Informed on Pharmaceutical and Health Technology Advances
As the pharmaceutical and healthcare landscape rapidly evolves, keeping up-to-date on developments like AI-driven diagnostic tools is essential. Subscribe to leading industry newsletters and publications to receive regular updates on technology breakthroughs, clinical advancements, and regulatory news impacting cancer care and beyond.
Focus Keyword: Avenda Health Unfold AI prostate cancer
